Caged Cell-Penetrating Peptide Conjugates for Selective Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted drug delivery systems face challenges in achieving specific cell targeting due to non-specific cell penetration by conventional cell-penetrating peptides (CPPs), leading to unintended tissue accumulation and reduced efficacy.
Innovation Solution
Development of caged cell-penetrating peptide (cCPP)-macromolecular carrier conjugates that utilize light-activated uncaging mechanisms to enhance selective intracellular delivery of diagnostic and therapeutic agents, allowing for precise targeting and uptake without the need for specific receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cell-penetrating peptides are used for intracellular delivery, then cell uptake efficiency is improved, but cell specificity deteriorates due to non-specific penetration
Solution Approach 1:
The patent applies preliminary action by caging the cell-penetrating peptide with a photolabile protecting group before administration. The caged peptide is administered systemically without causing non-specific uptake, then activated by light at the target site to enable selective cell penetration only where needed, thus maintaining both efficiency and specificity
Solution Approach 2:
The patent implements local quality by making the peptide's cell-penetrating property location-dependent through photoactivation. The peptide remains inactive (caged) in most of the body but becomes active only at the illuminated target site, creating local cell penetration capability that improves both uptake efficiency at the target and specificity by avoiding non-specific uptake elsewhere
2Reliability
If caged cell-penetrating peptide conjugates are used, then cell specificity is improved through light activation, but device complexity increases due to additional components
Solution Approach 1:
The patent merges multiple functions into a single conjugate structure: the caged cell-penetrating peptide, the macromolecular carrier, and the therapeutic or diagnostic agent are combined into one integrated molecule. This reduces the number of separate components needed while maintaining the ability to achieve selective delivery through light activation
Solution Approach 2:
The patent creates a universal delivery platform where the caged peptide-conjugate structure can carry various therapeutic or diagnostic agents and can be activated by light at different target sites. This multi-functional design achieves high specificity without requiring separate systems for different applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cCPP-based delivery system achieves efficient and selective penetration of therapeutic agents into target cells, including cancer cells, with high uptake rates and localized toxicity, while minimizing harm to healthy cells, thereby improving the efficacy of drug delivery and treatment outcomes.
Implementation Method 1
The photolabile protecting group undergoes photolytic degradation upon exposure to light, releasing the cell-penetrating peptide activity
Data Source
AI summary
The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticle pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.